Antitumour activity of N-[[1-[[2-(diethylamino)ethyl]amino]-9-oxo-9H-thioxanthen-4-yl]methyl]methanesulfonamide (WIN33377) and analogues

References

• LEGHA SS, GROSE WE, BODEY GP: Phase I study ofHycanthone. Cancer Treatment Reports (1978) 62(8):1173–1176.
   PubMedGoogle Scholar
• KOVACH JS, MOERTEL CG, SCHUTT AJ, EAGAN RT: Phase I study of Hycanthone. Cancer Treatment Reports (1979) 63:11–12.
   Google Scholar
• HAQ MM, LEGHA SS, WISEMAN CW, BODEY GP: Hepato-toxicity of Hycanthone in Patients with metastatic breast cancer. Cancer Treatment Reports (1980) 64:929–932.
   PubMedGoogle Scholar
• SCHUTT AJ, DALTON RJ, KOVACH JS, MOERTE CG, O'CON-NEL MJ: Phase II study of hycanthone in patients with advanced colorectal carcinoma. Cancer Treatment Reports (1983) 67:593–594.
   PubMedGoogle Scholar
• CORBETT TN: A selective two-tumor soft agar assay for drug discovery. AACR (1984) 25:325 (Abstr. 1289).
   Google Scholar
• CORBETT TN, WOZNIAK A, GERPHEIDE S, HANKA L: A selective two-tumor soft agar assay for drug discovery. In: In Vitro and In Vivo ModelsforDeWction of New Antitumor Drugs; 14th International Congress of Chemotherapy (1986). Hanka LJ, Kondo T, White RJ (Eds), University of Tokyo Press, Japan, pp. 5–14.
   Google Scholar
• LORLISSO PM, WOZNIAK AJ, POLIN L, CAPPS D, LEOPOLDWR, WERBEL LM, BIERNAT L, DAN ME, CORBETI"TH: Antitumor efficacy of PD115934 (NSC366140) against solid tumors of mice. Cancer Res. (1990) 50:4900–4905.
   PubMed Web of Science ®Google Scholar
• CORBETT TH, VALERIOTE FA, POLIN L, ET AL.: Discoveryof solid tumor active agents using a soft-agar-colony-formation disk-diffusion assay. In: Cytotoxic Anticancer Drugs: Models, and Concepts for Drug Discovery and Devel-opment. Valeriote FA, Corbett TN, Baker LH (Eds), Kluwer Academic Publishers, (1992) pp. 33–87, Boston/Dordrecht, London.
   Google Scholar
• BIERNAT L, POLIN L, CORBE'TT T: Adaptation of mam-mary tumors of mice to a soft-agar assay for use in drug discovery. Seventh NCI-EORTC Symposium on New Drugs in Cancer Therapy (1992). Abstract #185, Amsterdam, March 17–20.
   Google Scholar
• POLIN L, LOWICHIK N, PANCHAPOR C, PUGH S, KNIGHTJ, WHITE K, DEMCHIK L, JONES J, JONES L, CAVANAUGH P, MAI 1ES K, RAKE J, PERNI R, WENTLAND M, CORBEL 1 T: In vivo evaluation of thioxanthen-9-ones anti-solid tumor activity. AACR (1993) 34:434.
   Google Scholar
• BIERNAT L, LORUSSO P, LOWICHIK N, PANCHAPOR C, PUGH S, RAKE J, WENTLAND M, VALERIOTE F, BAKER L, CORBETT T: Preliminary evaluation of murine toxicities of thioxanthen-9-one antitumor agents. AACR (1993) 34:434.
   Google Scholar
• COUGHLIN SA, DANZ DW, KLINGBEL KM, ROBINSON RG,PERNI RB, WENTLAND MP, RAKE JB: Mechanism of action of 4-aminomentyl-thioxanthen-9-one anti-solid tumor agents. AACR (1993) 34:381.
   Google Scholar
• PERNI RB, WENTLAND MP, POWLES RG, CORBEL I TN,COUGHLIN SA, MATTES KC, RAKE JB: 4-Aminomethylthi-oxanthen-9-one anti-solid tumor agents. AACR (1993) 34:381.
   Google Scholar
• WENTLAND MP, PERNI RB, POWLES RG, KLINGBEIL KM,ROBINSON RG, RAKE JB: Thioxanthone antitumor agents: the effects of 7-methoxy and 7-hydroxy substi-tutions. AACR (1994) 35:397.
   Google Scholar
• WENTLAND MP, PERNI RB, POWLES RG, HLAVAC AG, MAI I ES KC, CORBETT TI-I, COUGHLIN SA, RAKE JB: Anti-solid tumor efficacy and preparation of N-([14[2-(diethylamino)ethyl]arnino]-9-oxo-9H-thioxanthen-4-ylimethyl] methanesuffonamide (WIN33377) and re-lated derivatives. Bioorganic and Medicinal Chemistry Letters (1994) 4(4):609–614.
   Web of Science ®Google Scholar
• This manuscript contains SAR data as well as chemical synthesis information.
   Google Scholar
• HORWITZ JP, MASSOVA LWIESE TE, BESLER BH, CORBETT TH: Comparative molecular field analysis of the antitu-mor activity of 911-thioxanthen-9-one derivatives against pancreatic ductal carcinoma-03. J. Med. Chem. (1994) 37:781–786.
   PubMed Web of Science ®Google Scholar
• This manuscript contains SAR data.
   Google Scholar
• GERAM RI, GREENBERG NH, MACDONALD MM, SCHU-MACHER AM, ABBOTT BJ: Cell culture screen, KB Proto-col 1600. Cancer Chemother. Rep. (1972) 3:17.
   Google Scholar
• SHOEMAKER RH, ABBOTT BJ, MACDONALD MM, MAYOJG, VENDITTI JM, WOLPERT-DEFILIPPES MK: Use of the KB cell line for in vitro cytotoxicity assays. Cancer Treat. Rep. (1983) 67:97.
   PubMedGoogle Scholar
• CORBETT T, VALER1OTE F, BAKER L: Is the P388 murine tumor no longer adequate as a drug discovery model? Invest. New Drugs (1987) 5:3–20.
   Web of Science ®Google Scholar
• SCHABEL FM JR, GRLSWOLD DP JR, CORBETT TH, LASTER WR JR, MAYO JG, LLOYD HH: Testing on the therapeutic activity against advanced solid tumors of man. In: Can-cer Drug Development, Part B. Methods in Cancer Research (1979). Vol. 17, Busch H, DeVita V Jr. (Eds), Academic Press, Inc., New York, pp. 3–51.
   Google Scholar
• SCHABEL JR. FM, SKIPPER HE, TRADER MW, LASTER Vt712 JR., GRISWOLD JR. DP, CORBETT TH: Establishment of cross-resistance profiles for new agents. Cancer Treat, Rep. (1983) 67:905–922.
   Google Scholar
• CORBETT TH, VALERIOTE FA: Rodent models in experi-mental chemotherapy. In: The Use of Rodent Tumors in Experimental Cancer Therapy.' Conclusions and Recommen-dations (1987). Kallman RE (Ed) Pergamon Press, Chapt. 50, pp. 233–247.
   Google Scholar
• CORBETT TH, BISSERY M-C, LORUSSO P-M, POLIN L: 5-Fluorouracil containing combinations in murine tu-mor systems. Invest. New Drugs (1989) 7:37–49.
   PubMed Web of Science ®Google Scholar